The impact of myelosuppression on quality of life of patients treated with chemotherapy
Future Oncology · 02.07.2024 · 20 (21) · 1515-1530
DOI: 10.2217/fon-2023-0513 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, online erschienen am 08.04.2024. Verfasst von Jeffrey Crawford und 3 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Duke Medicine, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Quality of Life, Antineoplastic Agents. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: G1 Therapeutics.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusions to correct anemia/thrombocytopenia are associated with transfusion reactions and volume overload. Trilaciclib, which is approved for reducing myelosuppression in patients with extensive-stage small cell lung cancer, together with several investigational agents in development for managing myelosuppression have the potential to improve QoL for patients on chemotherapy. Chemotherapy can cause side effects by killing blood-forming cells in the bone marrow. This is known as myelosuppression and leads to neutropenia (decreased neutrophils [white blood cells]), anemia (decreased red blood cells) and thrombocytopenia (decreased platelets). Neutropenia can increase the risk of getting an infection, and severe cases might result in patients being hospitalized. Both neutropenia and anemia can cause fatigue, which is often reported by patients as being the most draining symptom of chemotherapy. Thrombocytopenia increases the risk of bleeding and can cause patients with cancer to become even more scared and anxious. Myelosuppression due to chemotherapy is usually managed with delays or reductions in the amount of chemotherapy that patients receive, but this may worsen the disease. Other treatments, known as supportive care interventions, include growth factors, which stimulate the production of blood cells and red blood cell or platelet transfusions. However, having these treatments in addition to chemotherapy can be a burden to patients, and they can cause side effects such as bone pain and blood clots. A treatment called trilaciclib is approved by the US Food and Drug Administration for patients receiving certain types of chemotherapy for advanced small-cell lung cancer. Trilaciclib has been shown to reduce neutropenia, anemia and thrombocytopenia in these patients and improve their quality of life. Other drugs are also being assessed in clinical trials for preventing or treating myelosuppression in patients with different cancer types. In the future, these drugs may improve quality of life for patients on chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute, Duke Medicine, Durham, NC 27710, USA.
- Cone Health Cancer Center, Greensboro, NC 27403, USA.
- Patient Author, Chapel Hill, NC 27516, USA.
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA.
Förderung
- G1 Therapeutics
Zitieren
APA
Crawford, J., Herndon, D., Gmitter, K., & Weiss, J. (2024). The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncology, 20(21), 1515-1530. https://doi.org/10.2217/fon-2023-0513
Vancouver
Crawford J, Herndon D, Gmitter K, Weiss J. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncology. 2024;20(21):1515-1530. doi:10.2217/fon-2023-0513
BibTeX
@article{Crawford2024,
author = {Crawford, Jeffrey and Herndon, Dana and Gmitter, Katerina and Weiss, Jared},
title = {The impact of myelosuppression on quality of life of patients treated with chemotherapy},
journal = {Future Oncology},
year = {2024},
volume = {20},
number = {21},
pages = {1515--1530},
doi = {10.2217/fon-2023-0513}
}
EUVIMED